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The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most 
consistent markers of a bad prognosis for this disease. Dickkopf-3 (DKK3) is a 
secreted protein of the Dickkopf family of Wnt regulators. It functions as a tumor 
suppressor in a range of cancers, including neuroblastoma. MYCN was recently found 
to downregulate DKK3 mRNA. In this study, we show that MYCN knockdown in 
MYCN-amplified (MNA) neuroblastoma cell lines increases secretion of endogenous 
DKK3 to the culture media.  
MiRNAs are ~20-nt-long RNAs encoded by the genome that downregulate mRNAs 
by targeting the 3`untranslated region (3’UTR). Many miRNAs regulate genes 
involved in the pathogenesis of cancer and are extensively deregulated in different 
tumors. Using miRNA target prediction software, we found several MYCN-regulated 
miRNAs that could target the 3’UTR sequence of DKK3, including mir-92a, mir-92b 
and let-7e. Luciferase expression from a reporter vector containing the DKK3-3`UTR 
was decreased when this construct was cotransfected with mir-92a, mir-92b and let-
7e in HEK293 cells. Mutation of the mir-92 seed sequence in the 3’UTR completely 
rescued the observed decrease in reporter expression when cotransfected with mir-92a 
and mir-92b. Antagomir and miRNA-mimic transfections in neuroblastoma cell lines 
confirmed that DKK3 secretion to the culture media is regulated by these miRNAs. 
Consistent with reports from other cancers, we found DKK3 to be expressed in the 
endothelium of primary neuroblastoma samples and to be absent in tumors with 
MYCN amplification. These data demonstrate a previously unknown tumor promoting 
mechanism for MYCN-regulated miRNAs. 
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Introduction 
Neuroblastoma accounts for 7% of childhood malignancies and 15% of pediatric 
cancer-related deaths. It is a heterogeneous disease, ranging from spontaneous 
regression to metastatic tumors resistant to multimodal treatment,  as reviewed in 
(Maris et al., 2007). The clinical outcome depends on several prognostic factors, with 
gene copy amplification of the MYCN oncogene being the most consistent marker of 
aggressive disease (Brodeur and Seeger, 1986).  MYCN is a member of the MYC 
oncogene family, which also consists of c-myc and MYCL (Schwab, 2004; Schwab et 
al., 1983), and functions by up and downregulating genes directly by transcriptional 
binding or through indirect pathways or mediators. It is known to regulate a wide 
range of microRNAs (Buechner et al., 2010; Loven et al., 2010; Mestdagh et al., 
2010; Schulte et al., 2008) and is responsible for the methylation of target genes by 
activating methyltransferases, as well as affecting the chromatine structure (Liu et al., 
2007; Marshall et al., 2010). 
MicroRNAs (miRNAs) are small non-coding RNAs which participate in diverse 
biological processes including tumorigenesis by sequence-specific targeting of 
particular mRNAs, primarily in the 3’ untranslated region (UTR) (Bartel, 2009; Kwak 
et al., 2010). MiRNAs negatively regulate protein production by translational 
repression, mRNA destabilization or a combination of both (Filipowicz et al., 2008). 
In mammals, miRNAs were recently shown to act predominantly through mRNA 
degradation (Guo et al., 2010). 
DKK3 is a member of the Dickkopf family of secreted Wnt antagonists, including 
DKK1-4 and Soggy, a member resembling DKK3. The functions of other members of 
this family have been well elucidated, although the role of DKK3 still remains unclear 
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(Barrantes Idel et al., 2006; Niehrs, 2006). DKK3 is an N-glycosylated, secreted, 
tumor suppressor protein which inhibits proliferation, is of prognostic significance in 
neuroblastoma (Koppen et al., 2008; Revet et al., 2009) and functions as a tumor 
suppressor in a range of other tumors (Fong et al., 2009; Hoang et al., 2004; Hsieh et 
al., 2004; Lee et al., 2009; Maehata et al., 2008; Mizobuchi et al., 2008; Saeb-Parsy 
et al., 2008; Veeck et al., 2009; Yue et al., 2008). The tumor suppressor mechanisms 
of DKK3 include inhibition of the canonical Wnt signaling by blocking β-catenin 
translocation to the nucleus (Caricasole et al., 2003; Hoang et al., 2004; Lee et al., 
2009; Yue et al., 2008). However, DKK3 does not seem to affect Wnt/β-catenin 
signaling in neuroblastoma, thereby suggesting other mechanisms to suppress 
tumorigenicity in this tumor (Koppen et al., 2008). This indicates that DKK3 has 
functions beyond mere canonical Wnt inhibition.  
Previous reports have demonstrated that MYCN downregulates DKK3 at the mRNA 
level in neuroblastoma by inducing MYCN expression in non-amplified cell lines 
(Bell et al., 2007; Koppen et al., 2008). The expression of DKK3 mRNA in cell lines 
and tumor material was inversely correlated with MYCN, and variations in DKK3 
were solely attributed to changes in MYCN expression. No direct promoter binding 
was identified, which suggests an indirect regulatory mechanism (Koppen et al., 
2008). We therefore hypothesized that MYCN suppresses DKK3 through miRNAs.  
 
Results 
MYCN Knockdown Increases Secretion of DKK3 Proteins in MYCN-amplified 
Neuroblastoma Cell Lines 
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The expression of Dickkopf-3 (DKK3) mRNA has previously been shown to be 
inversely correlated with MYCN mRNA expression in neuroblastic tumors and 
neuroblastoma cell lines (Bell et al., 2007; Koppen et al., 2008).  
Using a tetracycline-inducible retroviral MYCN-shRNA expression system, we 
observed that MYCN knockdown increased the expression of DKK3 mRNA in the 
MYCN-amplified (MNA) neuroblastoma cell lines SK-N-BE(2) and Kelly (Figure 
1a). Since DKK3 is a secreted glycoprotein, we further investigated DKK3 protein 
levels in culture supernatants from SK-N-BE(2) and Kelly cells upon induced MYCN 
knockdown. As shown in Figures 1b and 1c, increased levels of secreted DKK3 
protein were detected. Similarly, SHEP Tet21N, a derivative of the MYCN single-
copy SHEP neuroblastoma cell line containing a constitutively expressed 
doxycycline-repressible MYCN gene, revealed increased DKK3 secretion into the 
culture media when induced to suppress MYCN expression (Figure 1d).  
These data clearly show an inverse correlation between MYCN expression and 
secretion of DKK3 proteins in neuroblastoma cell lines. 
 
Methylation Status of the DKK3 Promoter in Neuroblastoma  
Inactivation of DKK3 expression by promoter methylation has been shown in several 
cancers (Ding et al., 2009; Lee et al., 2009; Veeck et al., 2008). Because of this, we 
analyzed the methylation status of the DKK3 promoter in ten primary neuroblastoma 
(five MNA, five non-MNA) samples and five neuroblastoma cell lines (three MNA, 
two non-MNA) using methylation-specific PCR (MSP). The breast cancer cell lines 
MDA-MB231 and HS578T were used as methylated and non-methylated DKK3 
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promoter controls, respectively (Veeck et al., 2008). As shown in Figure 2, all 
neuroblastoma tumor samples and cell lines, irrespective of their MYCN status, 
showed specific amplification of the 150 bp band generated by the non-methylated 
primers.  
These data demonstrate that the expression of DKK3 is not regulated by promoter 
methylation in neuroblastoma.  
 
MYCN-regulated miRNAs are Potential Regulators of DKK3 Expression 
In order to investigate whether MYCN regulates DKK3 expression indirectly through 
miRNAs, we used three independent miRNA target prediction programs (TargetScan 
v5.1, Diana-microT 3.0 and MicroCosm) to identify miRNAs that could target the 
3’UTR of DKK3 transcripts. The analyses revealed that mir-92a, mir-92b and mir-32 
were predicted to target the DKK3-3’UTR at position 25-31 (site-1) by all three 
programs used. In addition, let-7 and mir-98 were predicted to target a seed sequence 
at position 550-556 (site-2) by Targetscan 5.1 and Diana-microT 3.0, while mir-363 
was predicted to target site-1 by Targetscan 5.1 and MicroCosm (Supplementary 
Figure 1a). We have recently shown that mir-92a, mir-92b and let-7 expression 
levels in MNA neuroblastoma cell lines are regulated by MYCN (Buechner et al., 
2010).  
 
Mir-92a, mir-92b and let-7e Target the 3’UTR Sequence of DKK3 
Several reports have shown a correlation between MYCN and mir-92a expression in 
neuroblastoma. Mir-92a is a member of the oncogenic mir-17-92 cluster that has been 
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documented to be transcriptionally activated by MYCN (Fontana et al., 2008; Loven 
et al., 2010; Schulte et al., 2008). We recently reported that both mir-92a and mir-92b 
are downregulated when MYCN expression is repressed by anti-MYCN shRNAs in 
MNA neuroblastoma cell lines (Buchner et al., 2010). Since mir-92a and mir-92b are 
both inversely correlated with MYCN expression and predicted to target DKK3, we 
decided to investigate these miRNA:DKK3-3’UTR interactions experimentally. In 
addition, we also investigated the binding of let-7e to the target sequence at site-2 of 
the DKK3-3’UTR.  
The full-length 3’UTR sequence of DKK3 was cloned downstream of the Firefly 
luciferase gene in the pMIR-REPORT vector (pMIR-DKK3). HEK-293 cells were 
cotransfected with pMIR-DKK3 and microRNA mimics of mir-92a, mir-92b, let-7e 
or a negative control miRNA (mir-NC). Luciferase assays revealed that an 
overexpression of mir-92a, mir-92b and let-7e significantly reduced luciferase 
activity from the reporter vector when compared to the negative control miRNA 
(Figure 3). We observed a 38%, 45% and 30% decrease in luciferase activity with 
mir-92a, mir-92b and let-7e, respectively. These results indicate efficient repression 
of the luciferase DKK3-3’UTR reporter since large-scale proteomics studies have 
revealed that most miRNA:mRNA interactions result in the silencing of 30% or less 
(Baek et al., 2008).  
 
To test whether mir-92a, mir-92b and let-7e downregulated the luciferase activity of 
pMIR-DKK3 through binding to the predicted target sites, we mutated the putative 
seed sequences at site-1 and site-2. When the site-1 mutated version of pMIR-DKK3 
(mut mir-92 seed) was coexpressed with mir-92a or mir-92b, the luciferase activity 
was rescued to levels similar to those observed for the negative control miRNA 
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(Figures 3a and 3b). Only a slight rescue of luciferase activity was observed when 
the site-2 mutated reporter vector (mut let-7 seed1) was cotransfected with let-7e 
(Figure 3c). In searching for alternative let-7e seed sequences in the DKK3-3’UTR 
sequence, the RNA22 miRNA software detected a new candidate seed sequence at 
position 180-185 (site-3) (Miranda et al., 2006) (Supplementary Figures 1b and 1c). 
The mutated version of site-3 alone (mut let-7 seed2), or in combination with the 
mutated site-2 (mut let-7 seed1+2), did not result in the major rescue of luciferase 
activity (Figure 3c).  
Since mir-92a is coexpressed with the other members of the mir-17-92 cluster, we 
also examined the effect of these miRNAs on the 3’UTR sequence of DKK3. 
Cotransfection of pMIR-DKK3 and the individual mir-17-92 miRNA mimics resulted 
in a slight decrease in luciferase activity by mir-19a and -19b, which was predicted to 
target DKK3 by Targetscan. Cotransfections with mir-17 or mir-20a had no effect 
when compared to the negative control. We unexpectedly observed an increase in 
luciferase activity when the reporter vector was cotransfected with mir-18a 
(Supplementary Figure 2).  
 
DKK3 Secretion is Regulated by mir-92a, mir-92b and let-7e in Neuroblastoma Cell 
Lines 
To investigate how changes in the expression of MYCN-regulated miRNAs influence 
secretion of DKK3 in neuroblastoma cell lines, we transfected the MNA 
neuroblastoma cell lines SK-N-BE(2) and Kelly with antimir-92a and -92b 
(antagomirs) to reduce the endogenous expression of these miRNAs. A stem-loop 
qRT-PCR assay revealed an approximate 50% decrease in mir-92b expression 
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compared to a negative control antagomir (antimir-NC) (Supplementary Figure 3a). 
After 72 h of antagomir treatment, secretion of DKK3 into the culture media was 
measured. As shown in Figure 4a, suppression of both mir-92a and mir-92b resulted 
in a 2-2.5 fold increase in DKK3 secretion.   
Next, we transfected the non-MNA neuroblastoma cell lines SH-SY-5Y and SK-N-
AS with the mir-92a, mir-92b and let-7e miRNA mimics. Transfection of SH-SY-5Y 
with the mir-92b mimic increased the cellular mir-92b levels approximately 100 fold 
(Supplementary Figure 3b). The overexpression of mir-92a and mir-92b resulted in 
a major reduction of secreted DKK3 proteins from SH-SY-5Y and SK-N-AS cells, 
while let-7e overexpression revealed a minor, but significant decrease (Figure 4b). 
Consistent with these results, DKK3 mRNA levels were reduced when SH-SY-5Y 
cells were transfected with miRNA mimics of mir-92a, mir-92b and let-7e 
(Supplementary Figure 4).  
In summary, these data show that the MYCN-regulated miRNAs mir-92a, mir-92b and 
let-7e reduce secretion of DKK3 proteins from human neuroblastoma cell lines. 
 
DKK3 is Expressed in Neuroblastoma Vasculature 
We investigated 25 primary neuroblastoma tissue samples from various biological 
subsets and clinical stages for the expression of DKK3 (Supplementary Table 2). 
Twenty of 26 samples revealed specific DKK3 staining of the endothelial cells of the 
tumor, though no staining was seen in the tumor cells themselves (Figure 5a). Co-
staining with CD31 (an endothelial marker) demonstrated a co-localization to the 
endothelium. The immunopositivity for DKK3 in the endotehelial cells was of a 
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different intensity between different tumors. The unfavorable MNA tumors 
demonstrated a very low or absent staining (Supplementary Table 2). Four 
ganglioneuromas were investigated and all were immunopositive for DKK3 in the 
tumor-derived ganglion cells, but not in the surrounding stroma (Figure 5b, 
Supplementary Table 2).  
  
Discussion 
MYCN-regulated miRNAs Decrease DKK3 Secretion from Neuroblastoma Cell 
Lines  
DKK3 is an established tumor suppressor gene that inhibits the proliferation of several 
cancers, including neuroblastoma (Abarzua et al., 2005; Chen et al., 2009; Koppen et 
al., 2008; Kurose et al., 2004; Mizobuchi et al., 2008; Sakaguchi et al., 2009). It has 
previously been shown that DKK3 mRNA levels are inversely correlated to MYCN 
mRNA expression in neuroblastic tumors and neuroblastoma cell lines (Bell et al., 
2007; Koppen et al., 2008). In our study, we used an inducible retrovirally delivered 
anti-MYCN shRNA to downregulate MYCN expression in two MNA neuroblastoma 
cell lines, and observed increased secretion of the endogenous DKK3 protein into the 
cell culture media. We also documented that the MYCN-regulated microRNAs, miR-
92a, mir-92b and let-7e, efficiently decreased expression of a luciferase reporter 
containing the 3’UTR sequence from DKK3. The predicted target seed sequence for 
mir-92a and mir-92b in the DKK3-3’UTR sequence was validated by mutagenesis. 
Two candidate seed sequences were found for let-7e. Mutation of the putative let-7e 
seed sequences, whether alone or in combination, could not rescue the let-7e 
repression of luciferase reporter expression similar to that observed for the mir-92 
13 
seed sequence. This indicates that other as yet unidentified let-7e seed sequences 
and/or let-7e targets are responsible for the majority of the observed DKK3 repression 
by let-7e. By the use of miRNA mimics and antagomirs treatment, we further 
demonstrated that both DKK3 mRNA expression and protein secretion into the media 
were inversely correlated to mir-92a, mir-92b and let-7e expression in neuroblastoma.  
Mir-92a is a member of the oncogenic mir-17-92 cluster, which consists of six 
coexpressed miRNAs: mir-17, mir-18a, mir-19a, mir-19b, mir-20 and mir92a 
(Mendell, 2008). Members of this cluster have been shown to be aberrantly expressed 
and to promote tumorigenicity in neuroblastoma (Beveridge et al., 2009; Fontana et 
al., 2008), as well as in other types of cancer (Diosdado et al., 2009; Hayashita et al., 
2005). Several reports have documented a correlation between the expression of 
MYCN and the mir-17-92 cluster (Fontana et al., 2008; Loven et al., 2010; Schulte et 
al., 2008). With the exception of mir-92a, and to some extent mir-19a and -19b, none 
of the other mir-17-92 members reduced expression of the DKK3 3’UTR luciferase 
reporter. On the contrary, we observed an unexpected increase in luciferase activity 
when mir-18a was overexpressed. A similar observation has previously been reported 
and was proposed to be due to interference between mir-18a and regulation of the 
CMV promoter (Vreugdenhil et al., 2009). 
 
The DKK3 Promoter is Not Inactivated by Hypermethylation in Neuroblastoma 
Hypermethylation of CpG islands in the promoter regions of genes is a powerful 
mechanism for transcriptional repression (reviewed in Illingworth and Bird, 2009). 
Nonetheless, the differential methylation of promoters is not a general mechanism for 
regulating gene expression since most inactive promoters remain unmethylated 
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(Weber et al., 2007). DKK3 is frequently inactivated by promoter methylation in 
cancers of the gastrointestinal tract, lung, cervix and breast (Ding et al., 2009; 
Kobayashi et al., 2002; Lee et al., 2009; Maehata et al., 2008; Sato et al., 2007; 
Veeck et al., 2009; Yue et al., 2008). For the neuroblastic tumors arising from the 
sympathetic adrenal lineage of the neural crest, increased DKK3 mRNA levels have 
been reported as a strong marker of differentiation. The well-differentiated 
ganglioneuromas showed a high DKK3 mRNA expression, while the undifferentiated 
neuroblastomas showed a low DKK3 expression, which also correlated with a bad 
prognosis (Koppen et al., 2008) 
The c-myc protein has previously been shown to repress gene expression through 
promoter hypermethylation by interaction with Miz-1 and Dnmt3a (Brenner et al., 
2005). Furthermore, global MYCN transcription factor binding analysis in 
neuroblastoma has revealed an association of the MYCN protein to regions of DNA 
hypermethylation (Murphy et al., 2009). 
We analyzed the methylation status of the DKK3 promoter in 10 neuroblastoma 
primary tumors and five neuroblastoma cell lines using methylation-specific PCR 
(MSP). The results revealed that neither the primary tumors nor the cell lines were 
hypermethylated at the investigated CpG island of the DKK3 promoter. In addition, a 
chromatin immunoprecipitation (ChIP) analysis performed by others failed to reveal a 
direct interaction between the MYCN protein and regulatory elements in the DKK3 
promoter (Koppen et al., 2008). Low levels of DKK3 have also previously been 
reported in the absence of promoter methylation in malignant melanoma cell lines 
(Kuphal et al., 2006).  
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These findings indicate that DKK3 levels in neuroblastoma are regulated by 
mechanisms other than promoter hypermethylation. Specifically, we have 
documented that mir-92a, mir-92b and let-7e target the 3’UTR sequence of DKK3 to 
repress its expression.  
 
DKK3 Expression in Tumor Endothelium is Inversely Correlated with MYCN 
Levels 
Recently, several papers have shown DKK3 to be involved in tumor vessel biology 
and to be highly expressed in tumor endothelium (Fong et al., 2009; Muhlmann et al., 
2010; Pei et al., 2009; Untergasser et al., 2008; You et al., 2010; Zenzmaier et al., 
2008). Consistent with these findings, we demonstrate an increased expression of 
DKK3 in neuroblastoma vasculature. It has been suggested that this vascular 
expression of DKK3 antagonizes the inactivation that frequently takes place in tumor 
cells during malignant transformation (Zenzmaier et al., 2008). DKK3 has also been 
reported to stimulate vascular growth and increase vascular density in tumors 
(Untergasser et al., 2008). The underlying mechanisms are not known, but 
bioinformatic analyses have indicated that DKK3 contains a cysteine-rich 
prokineticine domain also present in the potent angiogenic endocrine gland-derived 
vascular endothelial growth factor (EG-VEGF).  
We observed that the expression of the DKK3 protein in neuroblastoma vasculature 
was significantly higher in non-MNA tumors and more benign ganglioneuroma in 
comparison to MNA tumors. This is in line with a previous report by Valentijn and 
co-workers, who demonstrated higher levels of DKK3 mRNA expression in both non-
MNA neuroblastoma tumors and ganglioneuromas (Koppen et al., 2008).  
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The mir-17-92 cluster has been related to angiogenesis (Dews et al., 2006; Doebele et 
al.). A recent work demonstrated that the in vivo inhibition of mir-92a enhanced 
blood vessel formation (Bonauer et al., 2009). Here, we provide one possible 
explanation for this observation since DKK3 has been shown to stimulate 
angiogenesis (Untergasser et al., 2008).  
An increased serum level of mir-92a has also been reported to be of diagnostic value 
in colorectal cancer (Huang et al., 2009), although mir-92a has been shown to be 
downregulated in the serum of patients with acute lymphatic leukemia (Tanaka et al., 
2009). The mir-92a homologue, mir-92b, is a marker for primary brain tumors and 
regulates cell cycle control (Nass et al., 2009; Sengupta et al., 2009). DKK3 is present 
in high levels in the adult brain and central nervous system (Krupnik et al., 1999), 
thereby making it plausible that the link between mir-92b and DKK3 may play a 
contributing role in these cancers and deserves further investigation. Mir-92b is also a 
negative regulator of PRMT5, which is an epigenetic regulator of several tumor 
suppressors in vivo (Pal et al., 2007).  
In some cellular settings, DKK3 has been shown to stimulate growth and inhibit 
apoptosis. Additionally, DKK3 could also stimulate or inhibit the canonical wnt 
pathway, depending on the cellular context (Nakamura and Hackam, 2010; Nakamura 
et al., 2007). These contradictory findings illustrate the complex and cell specific 
nature of DKK3, so it therefore not surprising to find that DKK3 is regulated by 
miRNAs with postulated oncogenic as well as tumor suppressor functions. 
 
Material and Methods 
Cell Cultures and miRNA Overexpression 
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The human SH-SY-5Y neuroblastoma cell line was cultivated in a DMEM/Ham’sF12 
medium (1:1) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine 
and 1% NEAA (non-essential amino acid). The HEK-293 cell line was grown in 
DMEM supplemented with 10% FBS. The SK-N-AS, SK-N-BE(2), Kelly and SHEP 
Tet21N cell lines were grown in RPMI-1640 medium supplemented with 10% FBS. 
SHEP Tet21N cells express high MYCN in the absence of doxycycline (Lutz et al., 
1996). To switch off MYCN expression, 1 µg/ml doxycycline was added to the growth 
media at least 24 hours prior to the experiments. All cells were split before confluence 
and incubated at 37˚C in 5% humidity and 4.5% CO2. 
MicroRNA mimics (let-7e, mir-92a, -92b, -17, -18a, -19a, -19b and -20a) and 
antagomirs (antimir-92a and -92b), with corresponding negative controls, were from 
Shanghai GenePharma, (Shanghai, China). Transfections of miRNA mimics and 
antagomirs were carried out using Lipofectamine-2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. 
 
MYCN Knockdown 
SK-N-BE(2) and Kelly cells stably transfected with pcDNA6/TR (constitutively 
expressing the Tetracycline Repressor) were transduced with a retrovirus (RV-
aMN1658) containing a tetracycline-inducible anti-MYCN shRNA (aMN1658) 
expression module (Henriksen et al., 2010). Retroviruses containing an inducible 
scrambled shRNA (SCR) were used as a negative control, and cells were cultivated as 
previously described (Henriksen et al., 2007). Expression of the shRNAs was induced 
by adding 1 µg/ml doxocycline to the culture medium. 
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Human Tissue Samples 
Tissue samples from tumors were obtained from neuroblastoma patients during 
surgery, snap-frozen in liquid nitrogen and transferred to storage at -80°C for future 
analysis. Twenty-six neuroblastoma samples derived from children of different ages 
and all clinical stages, including different biological subsets, were analyzed 
(Supplementary Table 2). Five childhood ganglioneuromas from children aged 12-
25 months were also included. Genomic DNA was extracted from frozen (-70°C) 
tumor tissue according to standard procedures, and ethical approval was obtained by 
the Karolinska University Hospital Research Ethics Committee (approval 03-308). 
 
Methylation-specific PCR (MSP) 
DNA (100 ng) from neuroblastoma tumors or cell lines was bisulfite-treated using the 
EZ methylation gold kit (Zymo Research, CA, USA), and further purified using the 
DNA Clean and Concentrate Kit (Zymo). Previously published primers, specific to 
the methylated (ON-479/ON-480) and unmethylated sequence (ON-481/ON-482), 
were used to perform a methylation-specific PCR (MSP) on the promoter region of 
DKK3 (Sato et al., 2007). The primer sequences are listed in Supplementary Table 
1. The Zymotaq premix polymerase (Zymo) was used in a 25 µl reaction, including 
50 ng of treated template. Products were visualized on ethidium bromide-stained 3% 
agarose gels. We included DNA from the MDA-MB231 and HS578t as methylated 
and unmethylated controls, respectively (Veeck et al., 2008).  
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In Silico Target Prediction 
Diana microT v3.0 (www.microrna.gr/microT), EMBLs MicroCosm Targets v5 
(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) and TargetScan v5.1 
(www.targetscan.org/) target prediction software were used to identify miRNAs that 
could potentially target the human DKK3 3’UTR.  
 
Luciferase Reporter Assay 
The DKK3-3`UTR region was amplified from human total DNA (neuroblastoma 
LAN5 cell line) using primers ON-361 and ON-327 that contain in-fusion 
recombinase overhangs. The insert was cloned into the pMIR-REPORT vector 
(Ambion, Austin, TX, USA) using the In-Fusion Cloning Kit (Clontech, CA, USA) to 
generate pMIR-DKK3(wt). Mutations were introduced in the miRNA seed sequences 
at positions 25-31 (site-1), 550-556 (site-2) and 180-185 (site-3) using the Site-
Directed Mutagenesis Kit (Stratagene) with ON-447, ON-505 and ON-507 as primers 
to generate pMIR-DKK3(mut mir-92 seed), pMIR-DKK3(mut let-7 seed1) and 
pMIR-DKK3(mut let-7 seed2), respectively. A double mutant, pMIR-DKK3 (mut let-
7 seed1 + seed2), was also generated using ON-505 and ON-507 as primers. All 
vectors were verified by DNA sequencing using ON-005 and ON-363. The primer 
sequences are listed in Supplementary Table 1. 
Hek-293 cells grown in 12 well plates were Lipofectamin-2000-transfected with 25 
pmoles synthetic miRNA or negative control, 0.05 µg pGL-renilla vector (Promega, 
WI, USA) and 0.1 µg luciferase-UTR reporter vector (pMIR-DKK3(wt) and mutated 
versions). Luciferase was measured two days after transfection using the dual 
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luciferase reporter kit according to the manufacturer’s instructions (Promega). Firefly 
luciferase was normalized against renilla luciferase. All experiments were done in two 
parallels and at least three times.  
 
Quantitative Polymerase Chain Reaction (qPCR) 
SHSY5Y cells were seeded in 6-well plates and transfected with 100 pmoles of 
synthetic miRNAs. Cells were harvested 48 hours after transfection before total RNA 
was extracted and DNase-treated using the miRNeasy mini kit (Quiagen Inc., 
Valencia, CA, USA). 
cDNA was created using the miScript reverse transcriptase kit (Qiagen) and 1 ug 
RNA. Quantitative PCR was performed using the Power SYBR Green PCR Master 
Mix (Applied Biosystems Inc., Carlsbad, CA, USA). DKK3 mRNA levels were 
quantified using HPRT1 and UBC as housekeeping genes. 2.5 µl of a 20x diluted RT 
mix was loaded in a 25 µl reaction. The primer sequences are listed in 
Supplementary Table 1. 
Quantification of mir-92b was performed on the same cDNA using a miScript SYBR 
GREEN detection kit with mir-92b primer assay (Quiagen). HPRT1 and UBC were 
used for normalization. 
The ABI 7300 (Applied Biosystems) was used as a detection system. 
 
DKK3 Enzyme Linked Immunosorbent Assay (ELISA) 
SHSY5Y and SKNAS cells were seeded in 6-well plates, and transfected in three 
parallels with 100 pmol of synthetic miRNAs or a negative control miRNA. The cell 
21 
medium was changed 48 hours after transfection, and the cells were then incubated 
for another 24 hours before the conditioned medium was harvested for analysis using 
a DKK3 duoset Elisa assay (R&D Systems, Cambridge, UK). A high standard of 
2000 pmoles/ml was chosen and diluted to a low standard of 15 pmoles/ml.  
The transfection of antagomirs and the measuring of the DKK3 levels secreted by the 
SK-N-BE(2) and Kelly cell line were performed in the same manner as the 
overexpression of synthetic miRNAs (Shanghai GenePharma, China). The cell 
medium was changed 24 hours after transfection, while the harvesting of total cell 
protein and culture medium for ELISA was done after another 24 hours.  
The human neuroblastoma cell lines Kelly and SK-N-BE(2), containing RV-
aMN1658 and RV-SCR constructs, were incubated in the presence of 1 µg/ml 
doxycycline for six days before analyzing the DKK3 content in the medium 
(Henriksen et al., 2007). The medium was changed 24 hours before analysis. 
 
Levels of secreted DKK3 were normalized against total protein, measured at the time 




Formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene 
and graded alcohols, hydrated and washed in PBS. After antigen retrieval on sodium 
citrate buffer (pH 6) in a microwave oven, the endogenous peroxidase was blocked by 
0.3% H2O2 for 15 min. Sections were incubated overnight at 4°C with a biotinylated 
goat anti-human DKK3 antibody (R&D Systems). Thereafter, sections were incubated 
with streptavidin-HRP (Invitrogen) for 30 min at room temperature. A matched 
22 
isotype control was used as a control for nonspecific background staining. For co-
localization studies of DKK3 and CD31, tumor tissue sections were simultaneously 
stained with biotinylated anti-human DKK3 and mouse-anti-human CD31 (Dako, 
Glostrup, Denmark). For fluorescence visualization, streptavidin-Alexa Fluor 594 and 
anti-mouse Alexa Fluor 488 were used, respectively. 
 
Statistical Analysis 
All tests were performed two-sided. Differences between the two groups were studied 
using the two-sided Student`s t test. When more than two treatments were compared, 
we performed the one-way analysis of variance (ANOVA).  
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Figure Legends:  
 
Figure 1: MYCN knockdown increase Dickkopf-3 (DKK3) mRNA and secreted 
protein in neuroblastoma cells - (A) Real-time qRT-PCR measurements of DKK3 
mRNA levels in SK-N-BE(2) and Kelly cells induced to knock down MYCN 
expression. Secreted endogenous DKK3 proteins from (B) SK-N-BE(2) and (C) Kelly  
cells induced to knock down MYCN expression, and (D) SHEP Tet21N cells induced 
to repress exogenous MYCN overexpression were measured with ELISA.  
 
Figure 2: DKK3 promoter methylation status in neuroblastoma tumors and cell 
lines - Methylation-Specific PCR (MSP) was performed on bisulfite-treated DNA 
from neuroblastoma tumors and cell lines. Lanes labeled U and M contain PCR 
products amplified from primers recognizing unmethylated and methylated DKK3 
promoters, respectively. All neuroblastoma samples investigated were unmethylated. 
DNA from the breast cancer cell lines MDA-MB231 and HS578t were used as 
methylated and unmethylated controls, respectively (Veeck et al., 2008). NTC 
represents the no template control. MYCN-amplified samples are marked with . 
 
Figure 3: Luciferase assays for mir-92a, mir-92b and let-7e - Luciferase activity of 
HEK293 cells cotransfected with the wild type (pMIR-DKK3 wt) or mutated DKK3-
3’UTR luciferase vector and miRNA mimics of mir-92a (A), mir-92b (B) or let-7e 
(C). Mut mir-92 seed is mutated in the predicted mir-92 seed sequence at position 28-
30 
29 in DKK3-3’UTR. Similarly, mut let-7 seed1, mut let-7 seed2 and mut let-7 
seed1+2 were mutated in the predicted let-7 seed sequences at position 550-556, 180-
185 and 550-556+180-185 in DKK3-3’UTR, respectively. A plasmid constitutively 
expressing Renilla luciferase was used for normalization of the data. Data shown are 
mean ± SD of the ratio of normalized luciferase activity in miRNA mimic and control 




Figure 4: DKK3 ELISA analyses of culture media from neuroblastoma cell lines 
treated with antagomirs and miRNA mimics - (A) MNA neuroblastoma cell lines 
SK-N-BE(2) and  Kelly were transfected with antagomir-92a (antimir-92a), 
antagomir-92b (antimir-92b) or a negative control antagomir (antimir-NC). (B) Non-
MNA neuroblastoma cell lines SH-SY-5Y and SK-N-AS were transfected with mir-
92a, mir-92b, let-7e or negative control microRNA (mir-NC) mimics. Secretion of 
endogenous DKK3 proteins to the culture media was measured using an ELISA kit. 
Data shown are mean ± SD of the ratio of DKK3 proteins secreted to the culture 
media normalized to total protein in cell extracts of miRNA mimic/antagomir and 
control transfections. *P < 0.05 compared to antimir-NC or mir-NC. 
 
Figure 5: Immunohistochemical staining of Dickkopf-3 (DKK3) in 
neuroblastoma tumors - (A) A human neuroblastoma tissue section stained with a 
red fluorescently labeled (Alexa 594) anti-DKK3 monoclonal antibody, together with 
a green fluorescently labeled (Alexa 488) anti-CD31 monoclonal antibody. The nuclei 
were stained with DAPI, which are represented in blue. The merge represents an 
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overlay view of the DKK3, CD31 and DAPI image; 600x magnification. (B) 
Immunohistochemical staining of DKK3 in neuroblastoma primary tumors and 
ganglioneuromas showing specific staining of DKK3 in tumor vasculature (left 
image, sample no. 8, Supplementary Table 2) and in differentiated ganglion cells of a 
benign ganglioneuroma (right image, sample no. 28, Supplementary Table 2); 600x 
magnification.  
 
Supplementary Figure 1: MiRNA in silico analysis of DKK3-3’UTR - (A) Venn 
diagram displaying miRNAs computationally predicted to target the 3’UTR sequence 
of DKK3 by Diana-microT3.0, TargetScan v5.1 and MicroCosm. (B) Schematic 
overview from TargetScan v5.1 of the DKK3 3’UTR with conserved miRNA binding 
sites. (C) TargetScan v5.1 predictions of miRNAs that bind to the seed sequences at 
positions 25-31 (Site-1) and 550-556 (Site-2) of the DKK3 3’UTR. The RNA22 
miRNA software predicted let-7e to target DKK3-3’UTR at position 180-186 (Site-3). 
 
Supplementary Figure 2: Luciferase reporter assay for mir-17-92 members - 
MicroRNA mimics of the individual members of the mir-17-92 cluster were 
cotransfected with the pMIR-DKK3 vector into HEK293 cells. A plasmid 
constitutively expressing Renilla luciferase was used for normalization of the data. 
Data shown are mean ± SD of the ratio of normalized luciferase activity in miRNA 
mimic and control transfections. *P < 0.05. 
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Supplementary Figure 3: Mir-92b expression in SK-N-BE(2) and SH-SY-5Y cells 
treated with antagomir-92b and mir-92b mimic, respectively - (A) Relative 
expression of mir-92b in SK-N-BE(2) cells transfected with mir-92b antagomirs 
(antimir-92b). Antimir-NC = negative control antagomir. (B) Relative expression of 
mir-92b in SH-SY-5Y cells transfected with miRNA mimics of mir-92b. Mir-92b was 
measured using a stem-loop qRT-PCR assay for mir-92b. *P < 0.05. 
 
Supplementary Figure 4: DKK3 mRNA levels in SH-SY-5Y cells treated with 
miRNA mimics of mir-92a, mir-92b and let-7e - Relative expression of DKK3 
mRNA in SH-SY-5Y cells transfected with miRNA mimics of mir-92b. Mir-92b was 
measured using a stem-loop qRT-PCR assay for mir-92b. *P < 0.05. 
 
Supplementary Table 1: Overview of the oligonucleotide primers used in this 
study 
 
Supplementary Table 2: Neuroblastoma tumor and ganglioneuroma samples 
used in this study - aDiagnosis, bINSS=International Neuroblastoma Staging System, 
cPatient fulfilling clinico-biological criteria to obtain high-risk therapy, 
dNeuroblastoma, eGanglioneuroma, fNon-malignant adrenal gland, gMultifocal 
primary, hNo evidence of disease, iDied from disease, jAlive with disease, kDied of 
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pmir-DKK3 wt mut mir-92 seed mut mir-92 seed












































































































































Pos ition 25-31 of DK K 3 3' UTR
hs a-miR -92b




















Pos ition 550-556 of DK K 3 3' UTR
hs a-let-7e
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Supplementary Table 1.  
 
Primer:  Sequence (5’-3’): Description: 
   
   
ON-005 ATGGGCGGTAGGCGTGTA CMV sequencing primer 
ON-056 ATTTGGGTCGCGGTTCTTG qPCR UBC Forward 
ON-057 TGCCTTGACATTCTCGATGGT qPCR UBC Reverse 
ON-176 TGACACTGGCAAAACAATGCA qPCR HPRT1 Forward 
ON-177 GGTCCTTTTCACCAGCAAGCT qPCR HPRT1 Reverse 
ON-327 GATCAAGCTTCTATGGAAGATTTTTAATACAGG DKK3-3`UTR reverse  
ON-342 GATGTTCCGCGAGGTTGAGG qPCR DKK3 Forward 
ON-343 CCAACCTTCGTGTCTGTGTTGG qPCR DKK3 Reverse 
ON-361 AAAGCTGCGCACTAGTATCTGGACCAGGCTGTGGGTAGA Dkk3-3`UTR In-fusion cloning primer 
ON-363 ATCCTCATAAAGGCCAAGAA pMIR-report forward sequencing primer 
ON-447 TGTGGGTAGATGTGGTATAGAAATAGCTAA pMIR-report DKK3-mutagenesis 92a/b 
ON-448 GCAGTGTTGCTCAGCTCCTACCAGTGTGCCAGGGCAGC pMIR-report DKK3- mutagenesis let-7 
ON-479 CGAGTAGATTTAGTTCGGTTCGTAGC Methylated specific forward primer (DKK3) 
ON-480 CTTAACGTCGAATCCTACTCGAACG Methylated specific reverse primer 
ON-481 GAGTGAGTAGATTTAGTTTGGTTTGTAGT Unmethylated specific forward primer 








aDiagnosis, bINSS=International Neuroblastoma Staging System, cPatient fulfilling clinico-biological criteria to 
obtain high-risk therapy, dNeuroblastoma, eGanglioneuroma, fNon-malignant adrenal gland, gMultifocal primary, 
hNo evidence of disease, iDead of disease, jAlive with disease, kDead of surgical complications,    EC: 
Endothelial cells, GC: Ganglion cells 
 












1 NBd 21 M 1 no no 4n No NEDh +++ 
2 NB 123 F 1 no no 3n No NED ++ 
3 NB 7 F 1 yes yes 2n No DODi - 
4 NB 13 M 1 no no  No NED +++ 
5 NB 18 F 1 no no  No NED ++ 
6 NB 31 M 2B no no 3n No NED ++ 
7 NB 33 F 2A no no 3n No NED + 
8 NB 8 F 2 no no 3n No NED +++ 
9 NB 110 M 2 no no 2n No NED +++ 
10 NB 5 F 2 no no 3n No AWDj (+) 
11 NB 103 F 2B no no 2n No NED ++ 
12 NB  6 M 3 no nd 3n No NED     ++ 
13 NB 12 F 3 no no 5n No NED     ++ 
14 NB  0 M 3 no no 3n No DOCk + 
15 NB 79 M 3 yes yes 3n Yes NED (+) 
16 NB 136 M 4 yes yes 2n Yes DOD - 
17 NB 39 F 4 yes yes 2n Yes DOD - 
18 NB 35 F 4 no yes  Yes NED - 
19 NB 28 M 4 yes yes 3n Yes NED - 
20a NB 8 M 4Mg no no 3n No NED + 
20b NB 8 M 4M no no 4n/5n No NED + 
21 NB 22 M 4 yes yes  Yes DOD (+) 
22 NB 50 F 4 yes yes  Yes DOD (+) 
23 NB  0 M 4S no no 3n No NED ++ 
24 NB 10 M 4S no no 3n No NED +++ 
25 NB 0 M 4S no nd 4n No NED (+) 
          DKK3 
in GC  
26 GNe 145 M      NED +++ 
27 GN 30 F      AWD ++ 
28 GN 59 F      NED +++ 
29 GN 137 M      NED ++ 
           
